Latest Period
Q4 2025
Security Snapshot
Matinas BioPharma Holdings, Inc. - Common Stock, par value $0.0001 per share (MTNB) Institutional Ownership
CUSIP: 576810303
13F Institutional Holders and Ownership History from Q3 2024 to Q1 2026
Institutions Reporting
28
Shares (Excl. Options)
442,485
Price
$0.59
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place.
- Type / Class
- Equity / Common Stock, par value $0.0001 per share
- Symbol
- MTNB on NYSE
- Shares outstanding
- 5,086,994
- Price per share
- $0.55
- All holders as of 31 Dec 2025
- Q4 2025
- Total 13F shares
- 442,485
- Total reported value
- $260,280
- % of total 13F portfolios
- 0%
- Share change
- +112,379
- Value change
- +$3,912
- Number of holders
- 28
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Quick Takeaways
- MTNB - Matinas BioPharma Holdings, Inc. - Common Stock, par value $0.0001 per share is tracked under CUSIP 576810303.
- 28 institutions reported positions in Q4 2025.
- 5 significant owners is listed from Schedule 13D/13G reporting.
What Changed
- Holder count moved from 28 to 2 between Q4 2025 and Q1 2026.
- Reported value moved from $260,280 to $16,324.
Why This Matters
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Source Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 28 institutions filings for Q4 2025.
Investment Quick Answers
What is CUSIP 576810303?
CUSIP 576810303 identifies MTNB - Matinas BioPharma Holdings, Inc. - Common Stock, par value $0.0001 per share in SEC 13F datasets.
Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.
Continue With The Right Next Step
- Latest 13F filings - identify new institutional portfolio moves.
- Latest Schedule 13D/13G reports - cross-check beneficial ownership events.
- All institutional ownership pages - compare nearby CUSIPs and holder concentration.
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 576810303:
Significant Owners of Matinas BioPharma Holdings, Inc. - Common Stock, par value $0.0001 per share (MTNB) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Sanitam Partners LLC | 10% | -59% | $10,262,939 | +$9,526,394 | 17,104,899 | +1293% | STERN ADAM K | 08 Apr 2025 |
| Pembroke & Partners LLC | 10% | -50% | $10,137,427 | +$9,526,394 | 16,895,712 | +1559% | Robert J. Eide | 08 Apr 2025 |
| Lazar David E. | 9.8% | $517,750 | 545,000 | Lazar David E. | 15 Aug 2025 | |||
| Hezbay Holdings LLC | 5% | $533,066 | 253,841 | Hezbay Holdings LLC | 25 Sep 2025 | |||
| 111 Equity Group | 3.6% | -31% | $110,183 | -$47,617 | 183,639 | -30% | 111 Equity Group LLC | 13 Feb 2025 |
As of 31 Dec 2025, 28 institutional investors reported holding 442,485 shares of Matinas BioPharma Holdings, Inc. - Common Stock, par value $0.0001 per share (MTNB). This represents 8.7% of the company’s total 5,086,994 outstanding shares.
Institutional Holders of Matinas BioPharma Holdings, Inc. - Common Stock, par value $0.0001 per share (MTNB) across Reporting Periods
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 32,485 | $16,324 | -$250 | $0.55 | 2 |
| 2025 Q4 | 442,485 | $260,280 | +$3,912 | $0.59 | 28 |
| 2025 Q3 | 330,108 | $617,696 | +$101,472 | $1.89 | 28 |
| 2025 Q2 | 276,386 | $254,142 | -$21,440 | $0.89 | 24 |
| 2025 Q1 | 320,149 | $166,481 | -$25,649 | $0.52 | 23 |
| 2024 Q4 | 369,473 | $194,080 | -$555,641 | $0.51 | 20 |
| 2024 Q3 | 535,167 | $1,894,530 | +$1,718,769 | $3.54 | 16 |